NCT04614103Phase 2Recruiting

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Study sponsor: Iovance Biotherapeutics, Inc. · IOVA

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2030-12Estimated

Enrollment · participants170Estimated

Source updated2026-06-26Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Metastatic Non Small Cell Lung Cancer

Treatments or interventions studied

LN-145BiologicalAlso known as TIL, Autologous Tumor Infiltrating Lymphocytes
LN-145BiologicalAlso known as TIL, Autologous Tumor Infiltrating Lymphocytes

Primary outcomes · main study measures

measure: Objective Response Rate; description: To evaluate the efficacy of LN-145 as determined by objective response rate (ORR) in patients with metastatic NSCLC using the Response Evaluation Criteria in Solid Tumors (RECIST v1.1), as assessed by central review for Cohorts 1 and 2 and by the investigator for Cohorts 3, 4 and the Retreatment Cohort; timeFrame: Up to 60 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history